The German pharmaceutical industry is recovering slowly from the impact of the government's Health Structure Law, which led to considerable sales losses in 1993.
The drug industry association, the BPI, reports that a slight dip in April added to the relatively good growth in the first quarter of 1994 resulted in sales expanding by 4.6% for the first four months of this year. However, it also points out that foreign business was the driving force.
The BPI estimates that production will expand by 3%-5% in the whole of 1994, and so remain below the values of 1992. BPI director Ulrich Vorderwuehlbecke says that because the improvement is slow, currently restrictive investment and job policies in pharmaceutical companies will not change much for the time being.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze